文献速递肿瘤 PET/CT核素与放射性配体治疗

18F-FDG PET/CT对新辅助PD-1抑制剂治疗的非小细胞肺癌的预后价值:五年随访研究

Prognostic Value of 18F-FDG PET/CT in Neoadjuvant PD-1 Inhibitor-treated NSCLC: A Five-year Follow-up Study.
PubMed 文献 · Clin Nucl Med · 2025-06-04

该研究报告35例可切除非小细胞肺癌(NSCLC)患者接受2剂信迪利单抗后行肿瘤完全切除,并在基线和和新辅助治疗后行18F-FDG PET/CT检查,中位随访62.6个月,分析原发肿瘤、纵隔淋巴结、淋巴器官代谢参数及影像免疫相关不良事件的长期预后价值。

要点

  • 新辅助治疗后原发肿瘤低代谢(SULmax≤6.6、SULpeak≤4.0/3.9或SULmean≤2.7)患者无病生存,总生存改善(P=0.07、0.07、0.09)且无进展生存显著改善(P=0.01、0.02、0.02)。
  • 新辅助治疗后原发肿瘤MTV≤49.3或TLG≤41.0患者总生存显著改善(P=0.03和0.05)。
  • 基线淋巴结低代谢(SULmax≤4.6)患者无进展生存显著改善(P=0.04)。

核心结论

  • 这是首项报告18F-FDG PET/CT对新辅助免疫治疗后切除的NSCLC长期预后价值的研究。
  • 新辅助治疗后原发肿瘤低代谢和基线淋巴结低代谢是有望改善临床结局的预后标志物。

研究设计与样本

  • 共纳入35例NSCLC患者(29例男性,6例女性;中位年龄62岁)。
  • 患者接受2剂信迪利单抗,随后行肿瘤完全切除,并在基线和和新辅助治疗后行PET/CT扫描。
  • 分析PET/CT对总生存(OS)和无进展生存(PFS)的预后价值,聚焦原发肿瘤、纵隔淋巴结、淋巴器官的代谢参数及影像免疫相关不良事件。

主要发现

  • 中位随访62.6个月,新辅助治疗后原发肿瘤低代谢(SULmax≤6.6、SULpeak≤4.0/3.9或SULmean≤2.7)患者存活且无病,总生存改善(P=0.07、0.07、0.09),无进展生存显著改善(P=0.01、0.02、0.02)。
  • 新辅助治疗后原发肿瘤MTV≤49.3或TLG≤41.0患者总生存显著改善(P=0.03和0.05)。
  • 基线淋巴结低代谢(SULmax≤4.6)患者无进展生存显著改善(P=0.04)。

关键数值与推荐

  • 新辅助治疗后原发肿瘤SULmax≤6.6、SULpeak≤4.0/3.9或SULmean≤2.7与总生存改善相关(P=0.07、0.07、0.09),与无进展生存显著改善相关(P=0.01、0.02、0.02)。
  • 新辅助治疗后原发肿瘤MTV≤49.3或TLG≤41.0与总生存显著改善相关(P=0.03和0.05)。
  • 基线淋巴结SULmax≤4.6与无进展生存显著改善相关(P=0.04)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neoadjuvant immunotherapy has shown promising short-term outcomes of perioperative treatments for resectable non-small cell lung cancer (NSCLC) and is expected to release long-term survival benefits. Here, we reported the long-term prognostic value of 18F-FDG PET/CT over ∼a 5-year follow-up. PATIENTS AND METHODS: A total of 35 patients with NSCLC (29 males and 6 females; median age, 62 y) received 2 doses of sintilimab, followed by complete tumor resection and PET/CT scans at baseline and post-neoadjuvant stages. We investigated the prognostic value of PET/CT for overall survival (OS) and progression-free survival (PFS), focusing on metabolic parameters of primary tumors, mediastinal lymph nodes, lymphoid organs, and immune-related adverse events on imaging. RESULTS: During a median follow-up of 62.6 months, patients with low primary tumor metabolism (SULmax ≤6.6, SULpeak ≤4.0/3.9, or SULmean ≤2.7) at post-neoadjuvant scan were alive and disease-free, demonstrating improved OS (P = 0.07, 0.07, and 0.09) and significantly enhanced PFS (P = 0.01, 0.02, and 0.02); those with low metabolic tumor volume ≤49.3 or total lesion glycolysis ≤41.0 at post-neoadjuvant scan also had significantly improved OS (P = 0.03 and 0.05). Patients with low lymph node metabolism (SULmax ≤4.6) at baseline scan had significantly improved PFS (P = 0.04). CONCLUSIONS: This is the first study to report the long-term prognostic value of 18F-FDG PET/CT for resectable NSCLC after neoadjuvant immunotherapy. Low primary tumor metabolism at post-neoadjuvant scan and low lymph node metabolism at baseline scan are promising prognostic markers for improved clinical outcomes.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Tao X, Zhang Q, Li N, et al. Prognostic Value of 18F-FDG PET/CT in Neoadjuvant PD-1 Inhibitor-treated NSCLC: A Five-year Follow-up Study. Clin Nucl Med. 2025. PMID: 40462321. doi:10.1097/RLU.0000000000005910

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。